Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease
Bone Health awarded its fourth patent, marking a significant milestone in the journey of its product, Osteoboost. The wearable device is at the forefront of addressing osteopenia and osteoporosis